Cancer Cell 'Under Review': What Each Status Means and Realistic Timelines

Cancer Cell operates the Cell Press handling editor model with a small (around 5 editors) full-time editorial team. The handling editor reads the entire paper, typically writes notes on the submission, and consults the published literature via PubMed searches to understand the state of the field and compare the paper to what has been published.

A handling editor at Cancer Cell typically reviews 30 to 50 manuscripts per quarter and spends 60 to 90 minutes on the initial read, longer than at broader Cell Press titles because Cancer Cell's selective bar (8 to 10 percent acceptance) requires deeper editorial assessment.

Cell Press editorial culture at Cancer Cell is decisive: the 5-day desk-decision target reflects rapid editorial response. Cancer Cell's most distinctive feature is the post-review collaborative editor approach, after review, editors discuss with authors which reviewer points to prioritize and help focus on the main storyline. This collaborative approach distinguishes Cancer Cell from journals that simply forward reviewer reports.

Before the paper reaches external reviewers, a Cell Press handling editor at Cancer Cell evaluates whether the cancer-research significance warrants Cancer Cell's selective editorial slots. The 5-day desk-decision target reflects rapid editorial response: roughly 80 to 85 percent of submissions are rejected at this stage. A desk rejection most often means the handling editor concluded that the work would fit better at a sister Cell Press title (Cell Reports Medicine for clinical-translation, Cell Reports for broader biology, Cancer Discovery for basic-translation, iScience for open-access).

The Cell Press editorial office confirms files are complete: manuscript with figures embedded, supplementary information separate, reporting checklists where applicable (CONSORT for clinical trials, ARRIVE for animal work, MIQE for quantitative PCR), STAR Methods compliance documentation, cover letter directed to the editor, conflict-of-interest declarations, ethics-statement documentation, IRB approvals, and trial-registration documentation for clinical-trial papers.

The handling editor reads the paper, writes notes on the submission, and consults the published literature via PubMed searches to understand the state of the field and compare the paper to recently published work. Cell Press's 5-day desk-decision target at Cancer Cell reflects rapid editorial response.

In parallel with the handling editor's primary read, ambiguous-fit papers are discussed across the small (around 5 editors) Cancer Cell editorial team. The small-team structure means all ambiguous papers get full editor-team review rather than single-editor calls. This editorial-team discussion runs alongside the desk-screen and adds 2 to 4 days to the timeline that is invisible to the author in the portal.

Cell Press handling editors at Cancer Cell typically invite 2 to 3 external reviewers. The recruitment window can take 7 to 14 days because cancer-research reviewers with topic-matched expertise (e.g., cancer immunology, tumor biology, clinical oncology) are scarce. Cell Press journals consider 10 days sufficient time to complete a review.

Once reviewers agree to review, the typical Cancer Cell peer-review cycle lasts 10 to 21 days per reviewer. Reviewers are asked to evaluate cancer-research significance, methodological rigor, and reproducibility. Reviewer reports for Cancer Cell tend to be thorough; 2000 to 4000 word reports are typical given the 5-day desk decision selecting for high-quality papers.

After reports return, the handling editor synthesizes them, but Cancer Cell's distinctive feature is the post-review collaborative editor approach. Editors discuss with authors which reviewer points to prioritize and help focus on the main storyline before the formal decision. This collaborative process can add 7 to 14 days to the visible timeline but produces stronger revisions.

• Rejection within 1 to 3 days: Administrative issue or immediate scope mismatch.

• Rejection within 5 to 7 days: Handling editor desk rejection per the 5-day target.

• Still Under Review after 2 weeks: Strong signal. Paper passed the Cell Press filter.

• Still Under Review after 8 weeks: Reviewer-recruitment or reviewer-report delay. A polite inquiry to cancercell@cell.com is appropriate.

• Status changes to "Decision Pending": Reports are in; expect a decision within 1 to 2 weeks.

The user question is usually: "My paper has been Under Review for 5 weeks. Is that bad?" It is not bad by itself. At Cancer Cell, the more useful reading is that the paper likely cleared the fast Cell Press screen and is now waiting on reviewer recruitment, active reports, or editorial synthesis.

This is the most common anxiety we hear from Cancer Cell authors during the active editorial window. The honest answer: no, 5 weeks at Under Review puts you mid-cycle in Cancer Cell's active review distribution. Reports may already be in editorial synthesis with the handling editor entering the post-review collaborative author-discussion phase.

Most reviewer-driven delays come from reviewer-recruitment timing for cancer-research specialists rather than slow reviews, the 10-day Cell Press reviewer target keeps active review fast. If the portal still says Under Review at the 7-week mark, the most likely explanation is that the handling editor is in the author-discussion phase (Cancer Cell's distinctive feature) or that one of the assigned reviewers asked for an extension.

This is normal practice at Cell Press.

What you should NOT do during the 5-to-7-week window is email the editorial office. Cancer Cell's small editorial team manages 30+ active papers per editor; an inquiry at 5 weeks adds friction without accelerating the timeline.

If your Cancer Cell paper is rejected after review, papers can transfer with reviews to:

Cell Reports is the natural Cell Press cascade for broader cancer-biology work. Cell Press supports manuscript-transfer via the portable peer-review system, preserving reviewer reports. The transfer process takes 5 to 10 days.

Cell Reports Medicine is the Cell Press cascade for clinical-translational cancer papers where the clinical-translation framing fits.

iScience is the Cell Press open-access cascade for technically rigorous cancer-research papers where the open-access publishing model fits.

Cancer Discovery (AACR) is an AACR cascade option for translational-cancer papers. AACR operates independently from Cell Press; reports do not transfer.

Cell Press asks reviewers at Cancer Cell to evaluate four things specifically. The table below maps each to actionable preparation.

In our pre-submission review work across Cancer Cell manuscripts, we see three recurring patterns that explain most status anxiety after the page enters Under Review. The portal label itself is too coarse: the useful distinction is whether the manuscript is still being assessed for broad Cancer Cell fit, whether reviewers are testing the evidence package, or whether the handling editor is preparing the collaborative author-discussion stage. Generic Editorial Manager explainers rarely separate those paths; the journal-failure patterns below are what decide whether waiting time is good news or a delayed problem.

STAR Methods documentation gaps surface as reviewer requests for clarification.

For Cancer Cell, the status can look calm while reviewers are testing whether the methods section can support replication. When STAR Methods documentation is thin, especially for AAV constructs, organoid models, xenograft dosing, custom analysis code, imaging thresholds, or single-cell sequencing pipelines, reviewers consistently request expanded methods sections before issuing a final decision. This is different from a generic Cell Press status problem because Cancer Cell reviewers often connect the missing method detail to the strength of the cancer mechanism.

A paper can pass the handling editor screen and still lose momentum if figure legends, resource tables, and supplementary methods do not let a reviewer trace each claim back to a reproducible assay.

Narrow cancer-research framing flagged for broad-audience fit. Cancer Cell is not simply asking whether the result is interesting in one tumor model. When the introduction frames the work too narrowly around one cancer type, one biomarker, or one mechanism without broader cancer-research generalization, broad-audience concerns surface from at least one reviewer.

The strongest manuscripts use the abstract, first figure, and discussion to state the broader principle clearly: immune escape, lineage plasticity, resistance mechanism, tumor ecology, or translational target logic. If those manuscript components do not line up, "Under Review" is still positive, but the likely decision letter will ask for a sharper significance argument rather than only more experiments.

Cell Press venue mismatch flagged by handling editor. Cancer Cell editors can keep a manuscript Under Review while deciding whether reviewer reports support the flagship cancer-research claim or point toward a Cell Press transfer. When the handling editor concludes the work is sound but the cancer-research scope is narrower than Cancer Cell's bar, transfer offers to Cell Reports Medicine for clinical-translation, Cell Reports for broader biology, or iScience for open-access rigor are common.

The important preparation step is not refreshing the portal. It is mapping each likely reviewer concern to a revision, rebuttal, or transfer response before the decision arrives.

Check whether your Cancer Cell methods package will survive reviewer scrutiny →

Check whether your Cancer Cell framing is broad enough for the editorial bar →

This page was created from Cell Press's public author guidance at Cell Press author instructions, Cell Press Editorial Manager documentation, Cell Press editorial-speed guidance (5-day desk decision, 10-day reviewer target), the NCI Inside Cancer Careers podcast Episode 19 with the Cancer Cell editorial team describing the small-team structure and collaborative author-discussion phase, and Manusights pre-submission review experience with Cancer Cell-targeted manuscripts.

Source limitation: Cell Press can customize visible Editorial Manager labels and may hide internal status dates, so the guidance above interprets public status signals rather than private editorial notes.

For the Cell Press cancer-research landscape beyond Cancer Cell, see Cell Reports Medicine (clinical-translation), Cell Reports (broader biology, Cell Press portable peer-review transfer), iScience (open-access alternative), and sister AACR titles (Cancer Discovery, Cancer Research). The choice across these titles depends on whether the central contribution is top-cancer-research (Cancer Cell), clinical-translational (Cell Reports Medicine), broader biology (Cell Reports), open-access (iScience), or AACR-scope (Cancer Discovery, Cancer Research).

Reviewers at Cancer Cell typically draw from one cancer-research specialist and one broader-biology or methodologist. The Cancer Cell post-review collaborative author-discussion phase is distinctive, prepare a response template that engages with this phase rather than treating it as a one-way reviewer-feedback handoff.

For a pre-upload check of your manuscript against the Cancer Cell cancer-research-significance bar before submission, our Cancer Cell pre-submission diagnostic flags the STAR Methods gaps and narrow-framing weaknesses most likely to surface in reviewer reports.